139 related articles for article (PubMed ID: 38594780)
1. Pre-operative plasma VEGF-C levels portend recurrence in epithelial ovarian cancer patients and is a bankable prognostic marker even in the initial assessment of a patient.
Bhaskari J; Bhagat R; Shilpa V; Premalata CS; Krishnamoorthy L
J Ovarian Res; 2024 Apr; 17(1):77. PubMed ID: 38594780
[TBL] [Abstract][Full Text] [Related]
2. Expression levels of PTEN, HIF-1α, and VEGF as prognostic factors in ovarian cancer.
Shen W; Li HL; Liu L; Cheng JX
Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2596-2603. PubMed ID: 28678326
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor polymorphisms and a synchronized examination of plasma and tissue expression in epithelial ovarian cancers.
Bhaskari J; Premalata CS; Shilpa V; Rahul B; Pallavi VR; Ramesh G; Krishnamoorthy L
Tumour Biol; 2016 Jan; 37(1):1017-23. PubMed ID: 26264619
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor (VEGF) and cyclooxygenase 2 (COX 2) immunostaining in ovarian cancer.
Whynott RM; Manahan P; Geisler JP
Eur J Gynaecol Oncol; 2016; 37(2):164-6. PubMed ID: 27172738
[TBL] [Abstract][Full Text] [Related]
5. Expression of VEGF-A in Epithelial Ovarian Cancer: Correlation with Morphologic Types, Grade and Clinical Stage.
Premalata CS; Umadevi K; Shobha K; Anurekha M; Krishnamoorthy L
Gulf J Oncolog; 2016 May; 1(21):49-54. PubMed ID: 27250888
[TBL] [Abstract][Full Text] [Related]
6. Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer.
Sopo M; Anttila M; Hämäläinen K; Kivelä A; Ylä-Herttuala S; Kosma VM; Keski-Nisula L; Sallinen H
BMC Cancer; 2019 Jun; 19(1):584. PubMed ID: 31200683
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
8. Multivariate analysis by Cox proportional hazard model on prognosis of patient with epithelial ovarian cancer.
Wang M; He Y; Shi L; Shi C
Eur J Gynaecol Oncol; 2011; 32(2):171-7. PubMed ID: 21614907
[TBL] [Abstract][Full Text] [Related]
9. Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma.
Kucukgoz Gulec U; Gumurdulu D; Guzel AB; Paydas S; Seydaoglu G; Acikalin A; Khatib G; Zeren H; Vardar MA; Altintas A
Arch Gynecol Obstet; 2014 Feb; 289(2):393-8. PubMed ID: 23974278
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
[TBL] [Abstract][Full Text] [Related]
11. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer.
Seo SS; Song YS; Kang DH; Park IA; Bang YJ; Kang SB; Lee HP
Gynecol Oncol; 2004 Mar; 92(3):927-35. PubMed ID: 14984962
[TBL] [Abstract][Full Text] [Related]
12. The clinical and prognostic correlation of HRNPM and SLC1A5 in pathogenesis and prognosis in epithelial ovarian cancer.
Bjersand K; Seidal T; Sundström-Poromaa I; Åkerud H; Skirnisdottir I
PLoS One; 2017; 12(6):e0179363. PubMed ID: 28609484
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase isoenzyme-2 and vascular endothelial growth factor are associated with poor prognosis in esophageal adenocarcinoma.
Prins MJ; Verhage RJ; ten Kate FJ; van Hillegersberg R
J Gastrointest Surg; 2012 May; 16(5):956-66. PubMed ID: 22258871
[TBL] [Abstract][Full Text] [Related]
14. Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A [corrected].
Mathur SP; Mathur RS; Gray EA; Lane D; Underwood PG; Kohler M; Creasman WT
Gynecol Oncol; 2005 Sep; 98(3):467-83. PubMed ID: 15982726
[TBL] [Abstract][Full Text] [Related]
15. Serum Vascular Endothelial Growth Factor-A as a Prognostic Biomarker for Epithelial Ovarian Cancer.
Komatsu H; Oishi T; Itamochi H; Shimada M; Sato S; Chikumi J; Sato S; Nonaka M; Sawada M; Wakahara M; Umekita Y; Harada T
Int J Gynecol Cancer; 2017 Sep; 27(7):1325-1332. PubMed ID: 28557832
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma.
Yokoyama Y; Charnock-Jones DS; Licence D; Yanaihara A; Hastings JM; Holland CM; Emoto M; Umemoto M; Sakamoto T; Sato S; Mizunuma H; Smith SK
Br J Cancer; 2003 Jan; 88(2):237-44. PubMed ID: 12610509
[TBL] [Abstract][Full Text] [Related]
17. The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer.
Huang KJ; Sui LH
Med Oncol; 2012 Mar; 29(1):318-23. PubMed ID: 21264536
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer.
Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
Oncotarget; 2015 Sep; 6(29):28491-501. PubMed ID: 26143638
[TBL] [Abstract][Full Text] [Related]
19. [Vascular endothelial growth factor-C (VEGF-C) and vascular endothelial growth factor-D (VEGF-D) in ovarian carcinomas].
Rossochacka-Rostalska B; Gisterek I; Suder E; Matkowski R; Szelachowska J; Kornafel J
Ginekol Pol; 2006 Nov; 77(11):830-9. PubMed ID: 17378121
[TBL] [Abstract][Full Text] [Related]
20. Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer.
Sallinen H; Heikura T; Koponen J; Kosma VM; Heinonen S; Ylä-Herttuala S; Anttila M
BMC Cancer; 2014 Sep; 14():696. PubMed ID: 25245329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
